Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 May;65(3):266–277. doi: 10.1016/S0011-393X(04)80077-8

Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients

Fahri Yakaryilmaz 1,*, Sefa Guliter 1, Seren Ozenirler 1, Ozlem Erdem 2, Gulen Akyol 2
PMCID: PMC3964547  PMID: 24672082

Abstract

Background

Free radicals have a pivotal role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Decreasing oxidative stress might have beneficial effects on the biochemical and histologic progression of this disease.

Objective

We aimed to determine the therapeutic effect of vitamin E, a potent antioxidant, on liver enzymes and histology in NASH.

Methods

This 6-month, open-label study was conducted at the Departments of Gastroenterology and Pathology, Gazi University School of Medicine (Ankara, Turkey). Patients aged 18 to 70 years with biopsy-proven NASH were included in the study. All patients received vitamin E 800 U/d in 2 divided doses, orally (capsules) for 6 months. Patients were not advised to change their exercise or dietary habits. Body mass index (BMI) was calculated at months 0 (baseline) and 6. Histologic scoring of steatosis, necroinflammatory grade, and fibrosis stage was performed at 0 and 6 months. Liver enzyme activities (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and gamma-glutamyltransferase [GGT]) were monitored monthly. Control biopsy specimens were obtained at the end of the treatment. All of the liver biopsies were read by a single pathologist (G.A.) who was blinded to the clinical, laboratory, and histopathologic data, as well as the sequence of liver biopsies. Assessments of compliance and tolerability of treatment were performed using a pill count and patient interview, respectively, at the end of each month.

Results

Sixteen patients (12 men, 4 women; mean [SD] age, 45.5 [6.9] years [range, 37–60 years]) were enrolled. All patients completed 6 months of treatment. Mean BMI did not change significantly from baseline. Significant improvements in mean (SD) serum liver enzyme activities were observed at 6 months compared with baseline (ALT: 38.6 [16.3] U/L vs 84.8 [22.1] U/L, respectively, P = 0.001; AST: 29.8 [15.4] U/L vs 46.0 [16.0] U/L, respectively, P = 0.001; ALP: 154.6 [64.1] U/L vs 211.5 [70.4] U/L, respectively, P= 0.011; and GGT: 49.8 [38.5] U/L vs 64.7 [54.4] U/L, respectively, P = 0.002), as well as in total cholesterol level (176.2 [42.0] mg/dL vs 199.6 [60.6] mg/dL; P = 0.02). Posttreatment liver biopsy was available in 13 patients (81%). Significant improvements in the mean (SD) scores of steatosis (1.46 [0.66] vs 2.43 [0.62]; P = 0.002) and necroinflammatory grade (0.84 [0.24] vs 1.31 [0.51]; P= 0.006) were observed at 6 months compared with baseline, respectively. However, no significant change was noted in the mean (SD) score of fibrosis stage (0.77 [0.33] vs 1.12 [0.59], respectively). None of the patients reported any adverse effects.

Conclusion

In this small, 6-month, open-label study, vitamin E treatment was safe and well tolerated and led to potential biochemical and histologic improvements (except in fibrosis) in patients with NASH.

Full Text

The Full Text of this article is available as a PDF (2.1 MB).

Footnotes

This study was presented in poster format the 38th Annual Meeting of the European Association for the Study of the Liver, Istanbul, Turkey, March 29–April 1, 2003.

References

  • 1.Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis. 1999;19:221–229. doi: 10.1055/s-2007-1007111. [DOI] [PubMed] [Google Scholar]
  • 2.Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–723. doi: 10.1053/gast.2001.27126. [DOI] [PubMed] [Google Scholar]
  • 3.Powell EE, Cooksley WG, Hanson R. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80. doi: 10.1002/hep.1840110114. [DOI] [PubMed] [Google Scholar]
  • 4.Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol. 1989;20:594–598. doi: 10.1016/0046-8177(89)90249-9. [DOI] [PubMed] [Google Scholar]
  • 5.Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137–145. doi: 10.7326/0003-4819-126-2-199701150-00008. [published correction appears in Ann Intern Med. 1997; 137: 658] [DOI] [PubMed] [Google Scholar]
  • 6.James OF, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol. 1998;29:495–501. doi: 10.1016/s0168-8278(98)80073-1. [DOI] [PubMed] [Google Scholar]
  • 7.Matteoni CA, Younossi ZM, Gramlich T. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. doi: 10.1016/s0016-5085(99)70506-8. [DOI] [PubMed] [Google Scholar]
  • 8.Caldwell SH, Oelsner DH, Iezzoni JC. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology. 1999;23:664–669. doi: 10.1002/hep.510290347. [DOI] [PubMed] [Google Scholar]
  • 9.Newsome PN, Morgan K, Hayes PC. Cryptogenic cirrhosis—a disappearing disorder? Hepatology. 1999;30:438A. Abstract. [Google Scholar]
  • 10.Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9–13. doi: 10.1016/s0002-9343(99)00315-0. [DOI] [PubMed] [Google Scholar]
  • 11.Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis. 2001;21:57–69. doi: 10.1055/s-2001-12929. [DOI] [PubMed] [Google Scholar]
  • 12.Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev. 2002;60:289–293. doi: 10.1301/002966402320387224. [DOI] [PubMed] [Google Scholar]
  • 13.Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:797–810. doi: 10.1053/bega.2002.0327. [DOI] [PubMed] [Google Scholar]
  • 14.Laurin J, Lindor KD, Crippin JS. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology. 1996;23:1464–1467. doi: 10.1002/hep.510230624. [DOI] [PubMed] [Google Scholar]
  • 15.Guma C, Viola L, Thome M. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial. Hepatology. 1997;26:387A. Abstract. [Google Scholar]
  • 16.Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384A. doi: 10.1016/s0168-8278(99)80243-8. Abstract. [DOI] [PubMed] [Google Scholar]
  • 17.Marchesini G, Brizi M, Bianchi G. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–894. doi: 10.1016/s0140-6736(01)06042-1. [DOI] [PubMed] [Google Scholar]
  • 18.Neuschwander-Tetri BA, Brunt EM, Wehmeier KR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008–1017. doi: 10.1053/jhep.2003.50420. [DOI] [PubMed] [Google Scholar]
  • 19.Abdelmalek MF, Angulo P, Jorgenson RA. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol. 2001;96:2711–2717. doi: 10.1111/j.1572-0241.2001.04129.x. [DOI] [PubMed] [Google Scholar]
  • 20.Gulbahar O, Karasu ZA, Ersoz G. Treatment of nonalcoholic steatohepatitis with N-acetyl cysteine. Gastroenterology. 2000;118:1444A. Abstract. [Google Scholar]
  • 21.Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr. 2000;136:734–738. [PubMed] [Google Scholar]
  • 22.Hasegawa T, Yoneda M, Nakamura K. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther. 2001;15:1667–1672. doi: 10.1046/j.1365-2036.2001.01083.x. [DOI] [PubMed] [Google Scholar]
  • 23.Merat S, Malekzadeh R, Sohrabi MR. Probucol in the treatment of non-alcoholic steatohepatitis: A double-blind randomized controlled study. J Hepatol. 2003;38:414–418. doi: 10.1016/s0168-8278(02)00441-5. [DOI] [PubMed] [Google Scholar]
  • 24.Brunt EM, Janney CG, Di Bisceglie AM. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. doi: 10.1111/j.1572-0241.1999.01377.x. [DOI] [PubMed] [Google Scholar]
  • 25.Bellentani S, Chao YC, Ferretti I. Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid compositions in rats. Biochem Biophys Res Commun. 1996;220:479–483. doi: 10.1006/bbrc.1996.0430. [DOI] [PubMed] [Google Scholar]
  • 26.Hasegawa T, Yoneda M, Nakamura K. Long- and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1 gene expression. Hepatology. 1997;26:250A. Abstract. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES